Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,710,869
  • Shares Outstanding, K 101,247
  • Annual Sales, $ 1,887 M
  • Annual Income, $ 249,700 K
  • EBIT $ 579 M
  • EBITDA $ 583 M
  • 60-Month Beta 0.34
  • Price/Sales 7.24
  • Price/Cash Flow 52.33
  • Price/Book 5.03

Options Overview Details

View History
  • Implied Volatility 25.94% ( +0.10%)
  • Historical Volatility 26.97%
  • IV Percentile 7%
  • IV Rank 5.15%
  • IV High 94.83% on 08/06/24
  • IV Low 22.21% on 05/16/24
  • Put/Call Vol Ratio 0.16
  • Today's Volume 430
  • Volume Avg (30-Day) 432
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 16,138
  • Open Int (30-Day) 14,902

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.59
  • Number of Estimates 9
  • High Estimate 1.92
  • Low Estimate 1.33
  • Prior Year 1.44
  • Growth Rate Est. (year over year) +10.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.37 +10.66%
on 11/21/24
140.00 -3.27%
on 12/18/24
+12.13 (+9.84%)
since 11/20/24
3-Month
110.95 +22.05%
on 10/03/24
140.00 -3.27%
on 12/18/24
+17.07 (+14.42%)
since 09/20/24
52-Week
110.95 +22.05%
on 10/03/24
157.98 -14.28%
on 08/01/24
+15.11 (+12.56%)
since 12/20/23

Most Recent Stories

More News
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 135.42 (+0.34%)
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Investors in Neurocrine Biosciences, Inc. NBIX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov. 15, 2024 $80.00 Call had some of the highest...

NBIX : 135.42 (+0.34%)
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins

Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off.

MSFT : 436.60 (-0.10%)
SHOP : 108.95 (+1.76%)
LOW : 247.72 (+1.31%)
TDG : 1,276.15 (+1.27%)
NBIX : 135.42 (+0.34%)
AMD : 119.21 (+0.28%)
RKLB : 24.87 (+7.11%)
SONO : 14.56 (+1.04%)
HEI : 238.94 (+0.53%)
SYNA : 74.62 (-0.21%)
KFRC : 56.21 (-0.25%)
3 Top Growth Stocks to Buy at a Discount This Month

According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.

$IDX : 3,124.28 (+0.60%)
NBIX : 135.42 (+0.34%)
FLR : 50.34 (+0.52%)
$SPX : 5,930.85 (+1.09%)
SON : 49.42 (-1.46%)
Why Neurocrine Biosciences Stock Was Tumbling This Week

The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.

NBIX : 135.42 (+0.34%)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 1.1100 (-11.20%)
NBIX : 135.42 (+0.34%)
TAK : 13.10 (+0.69%)
AXSM : 90.73 (+1.10%)
BIIB : 146.47 (-0.62%)
Neurocrine: Q2 Earnings Snapshot

Neurocrine: Q2 Earnings Snapshot

NBIX : 135.42 (+0.34%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 135.42 (+0.34%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 135.42 (+0.34%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 135.42 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 139.80
2nd Resistance Point 138.41
1st Resistance Point 136.91
Last Price 135.42
1st Support Level 134.02
2nd Support Level 132.63
3rd Support Level 131.13

See More

52-Week High 157.98
Fibonacci 61.8% 140.01
Last Price 135.42
Fibonacci 50% 134.46
Fibonacci 38.2% 128.92
52-Week Low 110.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar